Corvus Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company focused on developing novel ITK inhibition therapies and immuno-oncology agents to treat cancer and immune diseases. The company offers soquelitinib (CPI-818), a first-in-class oral selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) for relapsed/refractory peripheral T-cell lymphoma (PTCL), moderate-to-severe atopic dermatitis, autoimmune lymphoproliferative syndrome (ALPS), and planned applications in metastatic renal cell cancer (RCC); ciforadenant (CPI-444), an oral small-molecule antagonist of the adenosine A2A receptor for advanced RCC in combination with ipilimumab and nivolumab; and mupadolimab (CPI-006), a humanized monoclonal anti-CD73 antibody evaluated in non-small cell lung cancer that promotes adenosine blockade and B-cell activation. Incorporated in 2014 and headquartered in Burlingame, California, Corvus conducts operations primarily in the United States with a strategic collaboration partner, Angel Pharmaceuticals Co. Ltd. in China, for soquelitinib in T-cell lymphomas and mupadolimab commercialization. In recent developments, Corvus completed enrollment in extension Cohort 4 of its Phase 1/1b trial of soquelitinib in refractory T-cell lymphomas, with full dataset results, including 8-week data from 24 atopic dermatitis patients, expected in January 2026 ahead of an ASH conference presentation on T-cell lymphoma data; the company plans to initiate a Phase 2 trial in atopic dermatitis and a Phase 1b/2 trial in RCC in early 2026. Interim Phase 1 data from soquelitinib in atopic dermatitis demonstrated a favorable safety and efficacy profile in moderate-to-severe patients. Financially, Corvus narrowed its Q3 2025 net loss to $10.2 million from $40.2 million year-over-year, driven by R&D investments, while maintaining focus on partnerships and pipeline expansion amid ongoing Phase 3 PTCL evaluation.
Company News
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 5.1% – Should You Buy?
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.